JP2024511029A - ＴＧＦ－β阻害剤及びその使用 - Google Patents

ＴＧＦ－β阻害剤及びその使用 Download PDF

Info

Publication number: JP2024511029A
Authority: JP; Japan
Prior art keywords: tgfβ; tumor; circulating; level; cancer
Prior art date: 2021-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2023557047A

Other languages

English (en)

Japanese (ja)

Inventor

シツアンリー－ヘフリッヒ

クリストファーブルックナー

コンスタンスマーティン

ライアンフォーセット

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scholar Rock Inc

Original Assignee

Scholar Rock Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-03-26

Filing date

2022-03-25

Publication date

2024-03-12

2022-03-25 Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc

2022-03-25 Priority claimed from PCT/US2022/022063 external-priority patent/WO2022204581A2/fr

2024-03-12 Publication of JP2024511029A publication Critical patent/JP2024511029A/ja

Status Pending legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 362
102000004887 Transforming Growth Factor beta Human genes 0.000 title claims description 479
108090001012 Transforming Growth Factor beta Proteins 0.000 title claims description 479
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title description 6
206010028980 Neoplasm Diseases 0.000 claims abstract description 794
201000011510 cancer Diseases 0.000 claims abstract description 190
238000002560 therapeutic procedure Methods 0.000 claims abstract description 113
238000000034 method Methods 0.000 claims abstract description 105
230000001225 therapeutic effect Effects 0.000 claims abstract description 50
238000011282 treatment Methods 0.000 claims description 205
239000000523 sample Substances 0.000 claims description 182
210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 181
210000004027 cell Anatomy 0.000 claims description 130
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 126
239000000427 antigen Substances 0.000 claims description 102
108091007433 antigens Proteins 0.000 claims description 102
102000036639 antigens Human genes 0.000 claims description 102
229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 97
239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 97
230000027455 binding Effects 0.000 claims description 93
210000004369 blood Anatomy 0.000 claims description 92
239000008280 blood Substances 0.000 claims description 92
238000005119 centrifugation Methods 0.000 claims description 53
239000003814 drug Substances 0.000 claims description 50
238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 49
230000009467 reduction Effects 0.000 claims description 49
239000012634 fragment Substances 0.000 claims description 45
101001004913 Homo sapiens Transforming growth factor beta activator LRRC33 Proteins 0.000 claims description 37
102100025954 Transforming growth factor beta activator LRRC33 Human genes 0.000 claims description 37
239000003446 ligand Substances 0.000 claims description 37
230000014509 gene expression Effects 0.000 claims description 29
208000006265 Renal cell carcinoma Diseases 0.000 claims description 26
230000007423 decrease Effects 0.000 claims description 26
108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
238000003556 assay Methods 0.000 claims description 22
125000003275 alpha amino acid group Chemical group 0.000 claims description 21
239000003795 chemical substances by application Substances 0.000 claims description 20
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 19
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 19
102100022338 Integrin alpha-M Human genes 0.000 claims description 19
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 19
230000002829 reductive effect Effects 0.000 claims description 18
102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims description 16
206010005003 Bladder cancer Diseases 0.000 claims description 16
101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims description 16
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 16
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 16
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 16
238000002512 chemotherapy Methods 0.000 claims description 16
229940079593 drug Drugs 0.000 claims description 16
230000001965 increasing effect Effects 0.000 claims description 16
201000001441 melanoma Diseases 0.000 claims description 16
230000005937 nuclear translocation Effects 0.000 claims description 16
238000001959 radiotherapy Methods 0.000 claims description 16
201000005112 urinary bladder cancer Diseases 0.000 claims description 16
231100000024 genotoxic Toxicity 0.000 claims description 15
230000001738 genotoxic effect Effects 0.000 claims description 15
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
230000002601 intratumoral effect Effects 0.000 claims description 12
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 12
102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims description 11
101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims description 11
206010009944 Colon cancer Diseases 0.000 claims description 10
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
239000003146 anticoagulant agent Substances 0.000 claims description 9
229940127219 anticoagulant drug Drugs 0.000 claims description 9
229960002768 dipyridamole Drugs 0.000 claims description 9
208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 claims description 8
201000008754 Tenosynovial giant cell tumor Diseases 0.000 claims description 8
239000001509 sodium citrate Substances 0.000 claims description 8
206010006187 Breast cancer Diseases 0.000 claims description 7
208000026310 Breast neoplasm Diseases 0.000 claims description 7
108010021064 CTLA-4 Antigen Proteins 0.000 claims description 7
208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
206010017758 gastric cancer Diseases 0.000 claims description 7
201000011549 stomach cancer Diseases 0.000 claims description 7
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
108091005735 TGF-beta receptors Proteins 0.000 claims description 6
102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 6
229960005305 adenosine Drugs 0.000 claims description 6
208000029742 colonic neoplasm Diseases 0.000 claims description 6
201000005202 lung cancer Diseases 0.000 claims description 6
208000020816 lung neoplasm Diseases 0.000 claims description 6
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
201000002528 pancreatic cancer Diseases 0.000 claims description 6
208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
229960000278 theophylline Drugs 0.000 claims description 6
206010044412 transitional cell carcinoma Diseases 0.000 claims description 6
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 6
229940038773 trisodium citrate Drugs 0.000 claims description 6
229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
238000002965 ELISA Methods 0.000 claims description 5
208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 5
101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 5
102000004211 Platelet factor 4 Human genes 0.000 claims description 5
108090000778 Platelet factor 4 Proteins 0.000 claims description 5
206010060862 Prostate cancer Diseases 0.000 claims description 5
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
206010038389 Renal cancer Diseases 0.000 claims description 5
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 5
201000010536 head and neck cancer Diseases 0.000 claims description 5
208000014829 head and neck neoplasm Diseases 0.000 claims description 5
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
201000010982 kidney cancer Diseases 0.000 claims description 5
206010061289 metastatic neoplasm Diseases 0.000 claims description 5
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
206010014733 Endometrial cancer Diseases 0.000 claims description 4
206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
108091092878 Microsatellite Proteins 0.000 claims description 4
206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 4
208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
208000037844 advanced solid tumor Diseases 0.000 claims description 4
201000010897 colon adenocarcinoma Diseases 0.000 claims description 4
238000002991 immunohistochemical analysis Methods 0.000 claims description 4
230000001394 metastastic effect Effects 0.000 claims description 4
208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 4
206010046766 uterine cancer Diseases 0.000 claims description 4
208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
239000012661 PARP inhibitor Substances 0.000 claims description 3
229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 3
206010041067 Small cell lung cancer Diseases 0.000 claims description 3
208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
201000004101 esophageal cancer Diseases 0.000 claims description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 3
201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
201000000062 kidney sarcoma Diseases 0.000 claims description 3
208000021039 metastatic melanoma Diseases 0.000 claims description 3
208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
201000002510 thyroid cancer Diseases 0.000 claims description 3
208000023747 urothelial carcinoma Diseases 0.000 claims description 3
208000017891 HER2 positive breast carcinoma Diseases 0.000 claims description 2
239000012472 biological sample Substances 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
108020001756 ligand binding domains Proteins 0.000 claims description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
230000001506 immunosuppresive effect Effects 0.000 abstract description 56
239000000203 mixture Substances 0.000 abstract description 29
230000004797 therapeutic response Effects 0.000 abstract description 27
238000012544 monitoring process Methods 0.000 abstract description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 75
108010029485 Protein Isoforms Proteins 0.000 description 73
102000001708 Protein Isoforms Human genes 0.000 description 73
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 70
230000004044 response Effects 0.000 description 69
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 68
238000001994 activation Methods 0.000 description 63
230000004913 activation Effects 0.000 description 63
201000010099 disease Diseases 0.000 description 60
238000012545 processing Methods 0.000 description 50
230000005764 inhibitory process Effects 0.000 description 49
238000011275 oncology therapy Methods 0.000 description 42
238000001574 biopsy Methods 0.000 description 41
108090000623 proteins and genes Proteins 0.000 description 40
102000006495 integrins Human genes 0.000 description 35
108010044426 integrins Proteins 0.000 description 35
206010062016 Immunosuppression Diseases 0.000 description 33
102000004169 proteins and genes Human genes 0.000 description 32
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 31
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 31
210000002744 extracellular matrix Anatomy 0.000 description 31
235000018102 proteins Nutrition 0.000 description 31
230000011664 signaling Effects 0.000 description 31
229940124639 Selective inhibitor Drugs 0.000 description 30
210000002865 immune cell Anatomy 0.000 description 30
229940124597 therapeutic agent Drugs 0.000 description 30
210000001744 T-lymphocyte Anatomy 0.000 description 29
206010061598 Immunodeficiency Diseases 0.000 description 28
239000003102 growth factor Substances 0.000 description 28
230000003472 neutralizing effect Effects 0.000 description 26
210000001519 tissue Anatomy 0.000 description 26
102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 description 25
108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 description 25
239000005557 antagonist Substances 0.000 description 25
230000000694 effects Effects 0.000 description 25
238000002648 combination therapy Methods 0.000 description 24
230000007717 exclusion Effects 0.000 description 24
210000002540 macrophage Anatomy 0.000 description 24
239000000306 component Substances 0.000 description 23
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
230000008901 benefit Effects 0.000 description 22
239000000090 biomarker Substances 0.000 description 21
239000000243 solution Substances 0.000 description 20
230000008859 change Effects 0.000 description 19
239000012740 non-selective inhibitor Substances 0.000 description 19
210000004981 tumor-associated macrophage Anatomy 0.000 description 19
108010005323 integrin alpha8beta1 Proteins 0.000 description 18
230000001988 toxicity Effects 0.000 description 18
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 17
238000001727 in vivo Methods 0.000 description 17
210000001616 monocyte Anatomy 0.000 description 17
206010028537 myelofibrosis Diseases 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000037361 pathway Effects 0.000 description 16
238000002203 pretreatment Methods 0.000 description 16
231100000419 toxicity Toxicity 0.000 description 16
208000035475 disorder Diseases 0.000 description 15
238000011269 treatment regimen Methods 0.000 description 15
108060003951 Immunoglobulin Proteins 0.000 description 14
238000012575 bio-layer interferometry Methods 0.000 description 14
230000006870 function Effects 0.000 description 14
102000018358 immunoglobulin Human genes 0.000 description 14
230000000495 immunoinflammatory effect Effects 0.000 description 14
238000009169 immunotherapy Methods 0.000 description 14
102000006354 HLA-DR Antigens Human genes 0.000 description 13
108010058597 HLA-DR Antigens Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
239000011159 matrix material Substances 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 13
102000004127 Cytokines Human genes 0.000 description 12
108090000695 Cytokines Proteins 0.000 description 12
206010016654 Fibrosis Diseases 0.000 description 12
210000004322 M2 macrophage Anatomy 0.000 description 12
230000000259 anti-tumor effect Effects 0.000 description 12
230000004761 fibrosis Effects 0.000 description 12
230000002401 inhibitory effect Effects 0.000 description 12
210000004698 lymphocyte Anatomy 0.000 description 12
238000012360 testing method Methods 0.000 description 12
102100040678 Programmed cell death protein 1 Human genes 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
238000009826 distribution Methods 0.000 description 11
230000008482 dysregulation Effects 0.000 description 11
230000001976 improved effect Effects 0.000 description 11
231100000682 maximum tolerated dose Toxicity 0.000 description 11
238000005259 measurement Methods 0.000 description 11
238000013188 needle biopsy Methods 0.000 description 11
229960002621 pembrolizumab Drugs 0.000 description 11
239000000092 prognostic biomarker Substances 0.000 description 11
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
230000035772 mutation Effects 0.000 description 10
229960003301 nivolumab Drugs 0.000 description 10
210000002381 plasma Anatomy 0.000 description 10
231100000041 toxicology testing Toxicity 0.000 description 10
241000282412 Homo Species 0.000 description 9
238000011374 additional therapy Methods 0.000 description 9
102000025171 antigen binding proteins Human genes 0.000 description 9
108091000831 antigen binding proteins Proteins 0.000 description 9
238000013459 approach Methods 0.000 description 9
229950002916 avelumab Drugs 0.000 description 9
230000000875 corresponding effect Effects 0.000 description 9
210000000987 immune system Anatomy 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
210000000651 myofibroblast Anatomy 0.000 description 9
230000036961 partial effect Effects 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
241000894007 species Species 0.000 description 9
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
101710089372 Programmed cell death protein 1 Proteins 0.000 description 8
241000700159 Rattus Species 0.000 description 8
230000002411 adverse Effects 0.000 description 8
239000012503 blood component Substances 0.000 description 8
238000004590 computer program Methods 0.000 description 8
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
229950009791 durvalumab Drugs 0.000 description 8
210000002950 fibroblast Anatomy 0.000 description 8
230000028993 immune response Effects 0.000 description 8
229920001184 polypeptide Polymers 0.000 description 8
208000003476 primary myelofibrosis Diseases 0.000 description 8
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 8
210000005166 vasculature Anatomy 0.000 description 8
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 7
102000009618 Transforming Growth Factors Human genes 0.000 description 7
108010009583 Transforming Growth Factors Proteins 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
210000001772 blood platelet Anatomy 0.000 description 7
210000001185 bone marrow Anatomy 0.000 description 7
230000001747 exhibiting effect Effects 0.000 description 7
230000005746 immune checkpoint blockade Effects 0.000 description 7
230000036039 immunity Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
230000010534 mechanism of action Effects 0.000 description 7
231100000062 no-observed-adverse-effect level Toxicity 0.000 description 7
230000000144 pharmacologic effect Effects 0.000 description 7
210000003289 regulatory T cell Anatomy 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
108010009992 CD163 antigen Proteins 0.000 description 6
102000008203 CTLA-4 Antigen Human genes 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 6
101000576894 Homo sapiens Macrophage mannose receptor 1 Proteins 0.000 description 6
102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
210000000612 antigen-presenting cell Anatomy 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
229960003852 atezolizumab Drugs 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
239000002458 cell surface marker Substances 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
230000001472 cytotoxic effect Effects 0.000 description 6
210000003162 effector t lymphocyte Anatomy 0.000 description 6
230000003176 fibrotic effect Effects 0.000 description 6
230000009545 invasion Effects 0.000 description 6
230000036210 malignancy Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
210000000066 myeloid cell Anatomy 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
150000003384 small molecules Chemical class 0.000 description 6
102000001398 Granzyme Human genes 0.000 description 5
108060005986 Granzyme Proteins 0.000 description 5
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
208000014767 Myeloproliferative disease Diseases 0.000 description 5
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 5
102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 5
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
230000006023 anti-tumor response Effects 0.000 description 5
229940121418 budigalimab Drugs 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
229940121420 cemiplimab Drugs 0.000 description 5
210000003690 classically activated macrophage Anatomy 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
239000000539 dimer Substances 0.000 description 5
238000010494 dissociation reaction Methods 0.000 description 5
230000005593 dissociations Effects 0.000 description 5
206010020718 hyperplasia Diseases 0.000 description 5
210000005008 immunosuppressive cell Anatomy 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000008595 infiltration Effects 0.000 description 5
238000001764 infiltration Methods 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
229960005386 ipilimumab Drugs 0.000 description 5
230000003902 lesion Effects 0.000 description 5
238000010801 machine learning Methods 0.000 description 5
230000003211 malignant effect Effects 0.000 description 5
208000037819 metastatic cancer Diseases 0.000 description 5
208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
230000008520 organization Effects 0.000 description 5
229930192851 perforin Natural products 0.000 description 5
239000003642 reactive oxygen metabolite Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
238000010186 staining Methods 0.000 description 5
238000011285 therapeutic regimen Methods 0.000 description 5
229940099456 transforming growth factor beta 1 Drugs 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 4
102000003886 Glycoproteins Human genes 0.000 description 4
108090000288 Glycoproteins Proteins 0.000 description 4
101000934372 Homo sapiens Macrosialin Proteins 0.000 description 4
102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 4
108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 4
102100025136 Macrosialin Human genes 0.000 description 4
108010085220 Multiprotein Complexes Proteins 0.000 description 4
102000007474 Multiprotein Complexes Human genes 0.000 description 4
206010028851 Necrosis Diseases 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 4
206010061535 Ovarian neoplasm Diseases 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
238000004422 calculation algorithm Methods 0.000 description 4
238000002619 cancer immunotherapy Methods 0.000 description 4
229940022399 cancer vaccine Drugs 0.000 description 4
238000009566 cancer vaccine Methods 0.000 description 4
230000004087 circulation Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
210000004602 germ cell Anatomy 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
230000006054 immunological memory Effects 0.000 description 4
238000012744 immunostaining Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
210000003071 memory t lymphocyte Anatomy 0.000 description 4
239000000178 monomer Substances 0.000 description 4
210000003643 myeloid progenitor cell Anatomy 0.000 description 4
230000017074 necrotic cell death Effects 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
230000007170 pathology Effects 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
238000004393 prognosis Methods 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000003439 radiotherapeutic effect Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000004043 responsiveness Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
229940066453 tecentriq Drugs 0.000 description 4
238000011287 therapeutic dose Methods 0.000 description 4
229940055760 yervoy Drugs 0.000 description 4
102000019034 Chemokines Human genes 0.000 description 3
108010012236 Chemokines Proteins 0.000 description 3
101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
-1 Itga11 Proteins 0.000 description 3
IVRXNBXKWIJUQB-UHFFFAOYSA-N LY-2157299 Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 IVRXNBXKWIJUQB-UHFFFAOYSA-N 0.000 description 3
102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 3
230000009830 antibody antigen interaction Effects 0.000 description 3
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000031018 biological processes and functions Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000011220 combination immunotherapy Methods 0.000 description 3
230000001461 cytolytic effect Effects 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
239000012636 effector Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
230000007705 epithelial mesenchymal transition Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
229950000456 galunisertib Drugs 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
238000000099 in vitro assay Methods 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
238000010827 pathological analysis Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000004983 pleiotropic effect Effects 0.000 description 3
208000037821 progressive disease Diseases 0.000 description 3
201000005825 prostate adenocarcinoma Diseases 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000008685 targeting Effects 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
238000009827 uniform distribution Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
UZOSBNQFZUJWFP-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide;hydrate Chemical compound O.CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C3=CC(=CC=C3N=CC=2)C(N)=O)=N1 UZOSBNQFZUJWFP-UHFFFAOYSA-N 0.000 description 2
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
101150008656 COL1A1 gene Proteins 0.000 description 2
208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
101150008975 Col3a1 gene Proteins 0.000 description 2
108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102100029995 DNA ligase 1 Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102100035233 Furin Human genes 0.000 description 2
108090001126 Furin Proteins 0.000 description 2
102000014015 Growth Differentiation Factors Human genes 0.000 description 2
108010050777 Growth Differentiation Factors Proteins 0.000 description 2
101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 2
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 2
101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 2
102000037982 Immune checkpoint proteins Human genes 0.000 description 2
108091008036 Immune checkpoint proteins Proteins 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
102000002698 KIR Receptors Human genes 0.000 description 2
108010043610 KIR Receptors Proteins 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028561 Myeloid metaplasia Diseases 0.000 description 2
201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 2
101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108091005682 Receptor kinases Proteins 0.000 description 2
108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 2
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
206010064390 Tumour invasion Diseases 0.000 description 2
102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 2
238000010306 acid treatment Methods 0.000 description 2
208000017733 acquired polycythemia vera Diseases 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000011319 anticancer therapy Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
229940112869 bone morphogenetic protein Drugs 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000009400 cancer invasion Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
230000006020 chronic inflammation Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
208000030381 cutaneous melanoma Diseases 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000011496 digital image analysis Methods 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
231100000371 dose-limiting toxicity Toxicity 0.000 description 2
229940056913 eftilagimod alfa Drugs 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
102000054751 human RUNX1T1 Human genes 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000005934 immune activation Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940125798 integrin inhibitor Drugs 0.000 description 2
229940043355 kinase inhibitor Drugs 0.000 description 2
238000002372 labelling Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
201000007270 liver cancer Diseases 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
201000005249 lung adenocarcinoma Diseases 0.000 description 2
201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
230000015654 memory Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000004802 monitoring treatment efficacy Methods 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
230000006780 non-homologous end joining Effects 0.000 description 2
244000309459 oncolytic virus Species 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000009038 pharmacological inhibition Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000003757 phosphotransferase inhibitor Substances 0.000 description 2
238000000678 plasma activation Methods 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
208000037244 polycythemia vera Diseases 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
108091011138 protein binding proteins Proteins 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000004447 silicone coating Substances 0.000 description 2
201000003708 skin melanoma Diseases 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000004448 titration Methods 0.000 description 2
238000012085 transcriptional profiling Methods 0.000 description 2
230000007704 transition Effects 0.000 description 2
102000035160 transmembrane proteins Human genes 0.000 description 2
108091005703 transmembrane proteins Proteins 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
CWOFQJBATWQSHL-DEOSSOPVSA-N (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid Chemical compound COCCN(CCCCc1ccc2CCCNc2n1)CC[C@H](Nc1ncnc2ccccc12)C(O)=O CWOFQJBATWQSHL-DEOSSOPVSA-N 0.000 description 1
ONKCBKDTKZIWHZ-MRWFHJSOSA-N (4r)-4-[[(2r)-6-amino-2-[[(2r)-2-[[4-(aminocarbamothioylamino)benzoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-5-[[(2r)-1-amino-6-[bis[2-[[4-[2-(1h-imidazol-5-yl)ethylamino]-4-oxobutanoyl]amino]acetyl]amino]-1-oxohexan-2-yl]amino]-5-oxope Chemical compound C([C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN(C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(=O)CNC(=O)CCC(=O)NCCC=1NC=NC=1)C(N)=O)NC(=O)C=1C=CC(NC(=S)NN)=CC=1)C1=CC=C(O)C=C1 ONKCBKDTKZIWHZ-MRWFHJSOSA-N 0.000 description 1
101150072006 33 gene Proteins 0.000 description 1
101150020966 Acta2 gene Proteins 0.000 description 1
102100036732 Actin, aortic smooth muscle Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
102000004452 Arginase Human genes 0.000 description 1
108700024123 Arginases Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229940125565 BMS-986016 Drugs 0.000 description 1
208000027188 Bifid uvula Diseases 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
208000013627 Camurati-Engelmann disease Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010264 Condition aggravated Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101710148291 DNA ligase 1 Proteins 0.000 description 1
102100035474 DNA polymerase kappa Human genes 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
208000013558 Developmental Bone disease Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102100027281 Fanconi anemia group F protein Human genes 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
101150099704 Fn1 gene Proteins 0.000 description 1
206010018276 Gingival bleeding Diseases 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000771075 Homo sapiens Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
101000863770 Homo sapiens DNA ligase 1 Proteins 0.000 description 1
101001094659 Homo sapiens DNA polymerase kappa Proteins 0.000 description 1
101000865085 Homo sapiens DNA polymerase theta Proteins 0.000 description 1
101001054659 Homo sapiens Latent-transforming growth factor beta-binding protein 1 Proteins 0.000 description 1
101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 description 1
101000619640 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 1 Proteins 0.000 description 1
101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101001004924 Homo sapiens Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
102000042838 JAK family Human genes 0.000 description 1
108091082332 JAK family Proteins 0.000 description 1
101150043981 LOXL2 gene Proteins 0.000 description 1
108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
208000001826 Marfan syndrome Diseases 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
208000032818 Microsatellite Instability Diseases 0.000 description 1
101150106019 Mmp2 gene Proteins 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
208000010718 Multiple Organ Failure Diseases 0.000 description 1
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229940126021 PLN-74809 Drugs 0.000 description 1
102100035031 Palladin Human genes 0.000 description 1
101710128215 Palladin Proteins 0.000 description 1
102000004503 Perforin Human genes 0.000 description 1
108010056995 Perforin Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
102100038603 Probable ubiquitin carboxyl-terminal hydrolase FAF-X Human genes 0.000 description 1
102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
108091007744 Programmed cell death receptors Proteins 0.000 description 1
238000003559 RNA-seq method Methods 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000003837 Second Primary Neoplasms Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
102000043168 TGF-beta family Human genes 0.000 description 1
108091085018 TGF-beta family Proteins 0.000 description 1
102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
101150000629 TGFB1 gene Proteins 0.000 description 1
238000012338 Therapeutic targeting Methods 0.000 description 1
208000033781 Thyroid carcinoma Diseases 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 description 1
101710169743 Transforming growth factor beta activator LRRC33 Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
102100035071 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
231100000230 acceptable toxicity Toxicity 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
108091022873 acetoacetate decarboxylase Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
229940049595 antibody-drug conjugate Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
229940062810 apitegromab Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000117 blood based biomarker Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000010001 cellular homeostasis Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
208000037966 cold tumor Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000006552 constitutive activation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000010252 digital analysis Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
108060002895 fibrillin Proteins 0.000 description 1
102000013370 fibrillin Human genes 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
229950004003 fresolimumab Drugs 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000004545 gene duplication Effects 0.000 description 1
238000011223 gene expression profiling Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000018578 heart valve disease Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
231100000171 higher toxicity Toxicity 0.000 description 1
238000013427 histology analysis Methods 0.000 description 1
230000007236 host immunity Effects 0.000 description 1
102000052917 human LRRC32 Human genes 0.000 description 1
102000053077 human LTBP1 Human genes 0.000 description 1
102000053454 human LTBP3 Human genes 0.000 description 1
102000048304 human NRROS Human genes 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000013388 immunohistochemistry analysis Methods 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
108091008042 inhibitory receptors Proteins 0.000 description 1
108010042442 integrin alphaEbeta7 Proteins 0.000 description 1
108010021315 integrin beta7 Proteins 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
238000012923 label-free technique Methods 0.000 description 1
210000004901 leucine-rich repeat Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004460 liquid liquid chromatography Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
210000001806 memory b lymphocyte Anatomy 0.000 description 1
208000037843 metastatic solid tumor Diseases 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000033607 mismatch repair Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000002625 monoclonal antibody therapy Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
210000001167 myeloblast Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
231100000989 no adverse effect Toxicity 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007331 pathological accumulation Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
239000013643 reference control Substances 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000036279 refractory period Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
229940124598 therapeutic candidate Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
208000013077 thyroid gland carcinoma Diseases 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
229950007217 tremelimumab Drugs 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
230000002100 tumorsuppressive effect Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Mycology (AREA)
Virology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP2023557047A 2021-03-26 2022-03-25 ＴＧＦ－β阻害剤及びその使用 Pending JP2024511029A (ja)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US202163166824P	2021-03-26	2021-03-26
US63/166,824		2021-03-26
US202163202260P	2021-06-03	2021-06-03
US63/202,260		2021-06-03
US202263302999P	2022-01-25	2022-01-25
US63/302,999		2022-01-25
US202263313386P	2022-02-24	2022-02-24
US63/313,386		2022-02-24
PCT/US2022/022063 WO2022204581A2 (fr)	2021-03-26	2022-03-25	Inhibiteurs de tgf-bêta et leur utilisation

Publications (1)

Publication Number	Publication Date
JP2024511029A true JP2024511029A (ja)	2024-03-12

Family

ID=88149091

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2023557047A Pending JP2024511029A (ja)	2021-03-26	2022-03-25	ＴＧＦ－β阻害剤及びその使用

Country Status (5)

Country	Link
EP (1)	EP4314831A2 (fr)
JP (1)	JP2024511029A (fr)
AU (1)	AU2022243575A1 (fr)
CA (1)	CA3213216A1 (fr)
IL (1)	IL306049A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2024187051A1 (fr) *	2023-03-07	2024-09-12	Scholar Rock, Inc.	Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients

2022
- 2022-03-25 CA CA3213216A patent/CA3213216A1/fr active Pending
- 2022-03-25 IL IL306049A patent/IL306049A/en unknown
- 2022-03-25 AU AU2022243575A patent/AU2022243575A1/en active Pending
- 2022-03-25 EP EP22723227.9A patent/EP4314831A2/fr active Pending
- 2022-03-25 JP JP2023557047A patent/JP2024511029A/ja active Pending

Also Published As

Publication number	Publication date
IL306049A (en)	2023-11-01
CA3213216A1 (fr)	2022-09-29
EP4314831A2 (fr)	2024-02-07
AU2022243575A1 (en)	2023-11-09

Publication	Publication Date	Title
JP7540994B2 (ja)	2024-08-27	高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
US20210340238A1 (en)	2021-11-04	TGFß1 INHIBITORS AND USE THEREOF
US20230050148A1 (en)	2023-02-16	Tgf-beta inhibitors and use thereof
US12122823B2 (en)	2024-10-22	Isoform-selective TGFB1 inhibitors and use thereof
US20230057012A1 (en)	2023-02-23	Tgfb inhibitors and use thereof
WO2022204581A2 (fr)	2022-09-29	Inhibiteurs de tgf-bêta et leur utilisation
JP2024511029A (ja)	2024-03-12	ＴＧＦ－β阻害剤及びその使用
EP4348260A2 (fr)	2024-04-10	Inhibiteurs de tgf-bêta et leur utilisation thérapeutique
US20240294623A1 (en)	2024-09-05	Tgf-beta inhibitors and therapeutic use thereof
WO2024187051A1 (fr)	2024-09-12	Inhibiteurs de tgf-bêta destinés à être utilisés pour traiter un cancer résistant ou réfractaire chez des patients

Legal Events

Date	Code	Title	Description
2024-01-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231116

Date

Code

Title

Description

2024-01-18

A521

Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116